Aya Nakaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Aya Nakaya has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Shosaku Nomura
First Department of Internal Medicine Kansai Medical University Osaka Japan
35 shared publicationsKazuyoshi Ishii
Kansai Medical University Medical Center, Osaka, Japan
25 shared publicationsMasaaki Hotta
First Department of Internal Medicine, Kansai Medical University, Japan
24 shared publicationsTomoki Ito
First Department of Internal Medicine, Kansai Medical University, Japan
24 shared publicationsHideaki Yoshimura
First Department of Internal Medicine, Kansai Medical University, Osaka 573‑1010, Japan
23 shared publicationsAtsushi Satake
First Department of Internal Medicine, Kansai Medical University, Osaka 573‑1010, Japan
22 shared publications
Latest Publications
- Open Access
- 25 September 2024
- Published by VM Media Group sp. z o.o in Hematology in Clinical Practice
The treatment of COVID-19-related autoimmune haemolytic anaemia
COVID-19-related autoimmune haemolytic anaemia (AIHA) has been reported since the onset of the pandemic. However, the precise aetiology is not fully understood and there is no consensus on the optimal treatment for COVID-19-related AIHA. To address this issue, we performed a literature review. Based on the available case reports, out of the 25 cases of COVID-19-related AIHA, 14 were diagnosed as warm AIHA and 11 as cold agglutinin disease (CAD). Thirteen out of the 14 warm AIHA cases were treated with steroids, while three were treated for CAD. Rituximab may be considered for use in steroid-refractory cases, with careful consideration of immunosuppression. Keywords: COVID-19 autoimmune haemolytic anaemia (AIHA) treatment steroid
- 25 September 2024
- Published by VM Media Group sp. z o.o in Hematology in Clinical Practice
Open AccessThe treatment of COVID-19-related autoimmune haemolytic anaemia
COVID-19-related autoimmune haemolytic anaemia (AIHA) has been reported since the onset of the pandemic. However, the precise aetiology is not fully understood and there is no consensus on the optimal treatment for COVID-19-related AIHA. To address this issue, we performed a literature review. Based on the available case reports, out of the 25 cases of COVID-19-related AIHA, 14 were diagnosed as warm AIHA and 11 as cold agglutinin disease (CAD). Thirteen out of the 14 warm AIHA cases were treated with steroids, while three were treated for CAD. Rituximab may be considered for use in steroid-refractory cases, with careful consideration of immunosuppression. Keywords: COVID-19 autoimmune haemolytic anaemia (AIHA) treatment steroid
- Open Access
- 17 November 2023
- Published by Elsevier in Leukemia Research Reports
- Vol. 20, 100395
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
- 17 November 2023
- Published by Elsevier in Leukemia Research Reports
- Vol. 20, 100395
Open AccessImpact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
- Open Access
- 1 September 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (17) , 2547-2551
Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm
An 84-year-old Japanese man was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We administered combination therapy using venetoclax and azacytidine. We observed neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3). After six cycles of treatment, the BPDCN abnormal cells in the bone marrow specimen almost disappeared, and atypical cells were not detected in a skin biopsy. We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events.
- 1 September 2023
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 62 (17) , 2547-2551
Open AccessVenetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm
An 84-year-old Japanese man was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We administered combination therapy using venetoclax and azacytidine. We observed neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3). After six cycles of treatment, the BPDCN abnormal cells in the bone marrow specimen almost disappeared, and atypical cells were not detected in a skin biopsy. We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events.
- Open Access
- 25 January 2023
- Published by Elsevier in Nefrología (English Edition)
- Vol. 43, 112-113
Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
- 25 January 2023
- Published by Elsevier in Nefrología (English Edition)
- Vol. 43, 112-113
Open AccessTreatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
- Open Access
- 3 August 2022
- Published by Elsevier in Nefrología
- Vol. 43, 111-112
Treatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
- 3 August 2022
- Published by Elsevier in Nefrología
- Vol. 43, 111-112
Open AccessTreatment of patients with COVID-19 on hemodialysis: Efficacy of remdesivir
- Open Access
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4-year overall survival (OS) of patients with maintenance (n = 82) was 80%, whereas that of patients without maintenance (n = 47) was 72% (p = 0.426). The 4-year progression-free survival (PFS) of patients with maintenance was 38%, whereas that of patients without maintenance was 27% (p = 0.088). Multivariate analysis revealed that an International Staging System score ≥2 was associated with worse PFS (hazard ratio 1.62, p = 0.043). Among the 129 patients, two were excluded owing to early relapse, 50 patients achieved complete response (CR), and 77 patients failed to achieve CR. Patients who achieved CR showed better 4-year PFS than those who failed to achieve CR (41% vs. 30%, p = 0.027); however, 4-year OS was not different (76% vs. 82%, p = 0.971). In patients who achieved CR, 4-year OS with/without maintenance was 74%/81% (p = 0.357), 4-year PFS with/without maintenance was 42%/40% (p = 0.954). In patients who failed to achieve CR, the 4-year OS with/without maintenance was 97%/91% (p = 0.107), and 4-year PFS with/without maintenance was 36%/16% (p < 0.001). In patients who failed to achieve CR, maintenance significantly improved the PFS. Maintenance after HDT/ASCT can prolong PFS in patients who fail to achieve CR in real-world settings.
Open AccessSignificance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum
A total of 129 symptomatic patients with multiple myeloma (MM) who underwent high-dose chemotherapy with autologous stem cell transplantation (HDT/ASCT) were analyzed. The 4-year overall survival (OS) of patients with maintenance (n = 82) was 80%, whereas that of patients without maintenance (n = 47) was 72% (p = 0.426). The 4-year progression-free survival (PFS) of patients with maintenance was 38%, whereas that of patients without maintenance was 27% (p = 0.088). Multivariate analysis revealed that an International Staging System score ≥2 was associated with worse PFS (hazard ratio 1.62, p = 0.043). Among the 129 patients, two were excluded owing to early relapse, 50 patients achieved complete response (CR), and 77 patients failed to achieve CR. Patients who achieved CR showed better 4-year PFS than those who failed to achieve CR (41% vs. 30%, p = 0.027); however, 4-year OS was not different (76% vs. 82%, p = 0.971). In patients who achieved CR, 4-year OS with/without maintenance was 74%/81% (p = 0.357), 4-year PFS with/without maintenance was 42%/40% (p = 0.954). In patients who failed to achieve CR, the 4-year OS with/without maintenance was 97%/91% (p = 0.107), and 4-year PFS with/without maintenance was 36%/16% (p < 0.001). In patients who failed to achieve CR, maintenance significantly improved the PFS. Maintenance after HDT/ASCT can prolong PFS in patients who fail to achieve CR in real-world settings.
- 21 January 2021
- Published by Wiley in European Journal of Haematology
- Vol. 106 (4) , 555-562
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
Objectives: This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).Methods: We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.Result: At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.Conclusion: This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.
- 21 January 2021
- Published by Wiley in European Journal of Haematology
- Vol. 106 (4) , 555-562
Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
Objectives: This study aimed to investigate real‐world data of ixazomib plus lenalidomide and dexamethasone (IRd) therapy for patients with relapsed and refractory multiple myeloma (RRMM).Methods: We retrospectively analyzed 122 patients treated with IRd at 16 centers from May 2017 to January 2019 by using the Kansai Myeloma Forum database.Result: At the start of IRd, the median age was 72 years, 66.7% of patients had IgG type, and the median number of prior therapies was 4, comprising bortezomib (85.4%) and lenalidomide (89.3%)‐based regimens. Disease progression and adverse events accounted for treatment discontinuation in 46 and 32 patients, respectively. The median overall survival (OS) was not reached, and the median progression‐free survival (PFS) was 11.9 months. Sensitivity to bortezomib did not affect the PFS, whereas lenalidomide‐refractory patients had significantly lower PFS than lenalidomide‐sensitive patients, who were comparable to TOURMALINE‐MM1 study. The patients with IgG type had significantly better PFS and OS than those with non‐IgG type.Conclusion: This study presents the largest real‐world data of patients treated with IRd in Asia. However, in real clinical practice, the patient background is different from the TOURMALINE‐MM1 study, and IRd showed poor efficacy, especially in the non‐IgG type and lenalidomide‐refractory patients with RRMM.
- 21 September 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (4) , 435-438
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry
We retrospectively analyzed the clinical features and outcomes in a real-world cohort of adolescents and the young adult (AYA) patients (age between 16 and 39 years) with symptomatic multiple myeloma (MM) registered with the Kansai Myeloma Forum. 26 patients had been diagnosed as symptomatic MM out of 3284 patients. The prevalence of AYA-MM was 0.8% in this cohort. 81% of the patients was received stem cell transplantation, which may improve outcome. Anemia and hypercalcemia might be prognostic factors, however International Staging System failed to predict overall survival. Five patients developed late-onset adverse events which were serious and life-threatening. The 5-year overall survival was 71.0%. We need to develop the new strategy to overcome AYA-MM.
- 21 September 2020
- Published by Springer Nature in International Journal of Hematology
- Vol. 112 (4) , 435-438
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry
We retrospectively analyzed the clinical features and outcomes in a real-world cohort of adolescents and the young adult (AYA) patients (age between 16 and 39 years) with symptomatic multiple myeloma (MM) registered with the Kansai Myeloma Forum. 26 patients had been diagnosed as symptomatic MM out of 3284 patients. The prevalence of AYA-MM was 0.8% in this cohort. 81% of the patients was received stem cell transplantation, which may improve outcome. Anemia and hypercalcemia might be prognostic factors, however International Staging System failed to predict overall survival. Five patients developed late-onset adverse events which were serious and life-threatening. The 5-year overall survival was 71.0%. We need to develop the new strategy to overcome AYA-MM.